Peptides of China — our platform for china peptides sourcing — publishes short updates like this one whenever something material changes: catalog additions, quality-process notes, and sourcing announcements. The substance of this update is below.
Peptides of China has expanded its public catalog to more than 140 unique products. One of the most exciting new additions is SLU-PP-915—an orally active, next-generation pan-ERR agonist now available in tablet form.
Hot New Arrival: SLU-PP-915 Tablets Are Now Available
The Peptides of China catalog continues to grow.
We have recently added several new research compounds, bringing our public catalog to more than 140 unique products. One of the most exciting additions is SLU-PP-915, now available in tablet form.
SLU-PP-915 belongs to a new generation of synthetic compounds being studied for their ability to activate estrogen-related receptors ERRα, ERRβ, and ERRγ. These nuclear receptors play an important role in the regulation of mitochondrial function, cellular energy utilization, fatty-acid oxidation, and oxidative metabolism.
Despite their name, estrogen-related receptors are not classical estrogen receptors and are not activated by estrogen.
What Makes SLU-PP-915 Different from SLU-PP-332?
Both SLU-PP-915 and SLU-PP-332 are pan-ERR agonists, meaning that they activate all three major ERR isoforms. They should not, however, be viewed simply as different versions or strengths of the same compound.
SLU-PP-332 is the earlier and more extensively studied research compound. Preclinical studies in mice have associated it with activation of exercise-related metabolic pathways, increased energy expenditure, enhanced fatty-acid oxidation, improved exercise capacity, and reduced fat accumulation.
SLU-PP-915 is a chemically distinct compound developed using a different molecular scaffold. Its primary advantage is oral activity: it was specifically developed to improve drug-like properties and has demonstrated oral bioavailability and in-vivo activity in animal research.
In simple terms:
- SLU-PP-332 is the earlier research prototype with a larger body of preclinical metabolic data.
- SLU-PP-915 is a newer, chemically distinct pan-ERR agonist developed as an orally active research candidate.
Recent preclinical research found that orally administered SLU-PP-915 enhanced aerobic exercise capacity and activated gene pathways associated with mitochondrial and oxidative metabolism in mice.
Available Now in Tablet Form
SLU-PP-915 is now available through the Peptides of China public catalog:
https://peptidesofchina.com/catalog/slu-pp-915
With more than 140 unique products now publicly listed, Peptides of China continues to expand access to both established research compounds and rare, emerging molecules that are often difficult to source.
More new products and important catalog updates are coming soon. Stay tuned.
SLU-PP-915 remains an investigational compound. Published evidence is preclinical, and its safety and efficacy in humans have not been established.
For laboratory and research use only. Not for human consumption.
Scientific References
- Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Related Products
China Peptides Sourcing Perspective
For catalog listings, batch specifications, and ordering information, see the catalog or how sourcing works.